Meanwhile, Kaplan–Meier curve statistical analysis of the results for NSCLC and its two major subtypes, i.e., lung adenocarcinoma and lung squamous cell carcinoma, implies that SMARCA2 is a potential target for therapeutic use and a promising prognostic marker of NSCLC. This evidence concerns the gene SMARCA2 and non-small cell lung carcinoma.